06:52 EDT Rapport Therapeutics (RAPP) files $400M mixed securities shelf
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics Elects New Directors at Annual Meeting
- Rapport Therapeutics management to meet with Citizens JMP
- Rapport Therapeutics Completes Enrollment for Phase 2a Trial
- Rapport Therapeutics Reports Q1 2025 Financial Results
- Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments